Profiel
Michael Casia has held positions as Chairman & Managing Director at Organon Canada, Inc. and Director at Biosimilars Canada.
Actieve functies van Mike Casia
Bedrijven | Functie | Begin |
---|---|---|
Biosimilars Canada
Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Directeur/Bestuurslid | - |
Organon Canada, Inc. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Biosimilars Canada
Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Commercial Services |
Organon Canada, Inc. |